Patients suspected to have CGD undergo functional testing including flow cytometry or immunoblotting for NADPH oxidase proteins, ROS production by dihydrorhodamine (DHR), cytochrome C reduction, and/or nitroblue tetrazolium (NBT) reduction assay (Figure 1). The gene discussed is FMO5; the disease is chronic granulomatous disease.